Perceive Biotherapeutics, Inc. announced the completion of enrollment in the phase 2a JOURNEY study, its phase 1/2a clinical study of VOY-101 in patients with geographic atrophy (GA). According to a company press release, the study exceeded the planned enrollment of 62 eyes to enroll 94 eyes (47 participants).

The study is a randomized, open-label, multicenter evaluation of a single intravitreal injection of VOY-101 at the recommended phase 2 dose established in phase 1. Participants have bilateral GA lesions that are well matched in size and 1 eye, selected by randomization, was treated with VOY-101 while the untreated fellow eye serves as the within-patient control—controlling for genetics, environmental exposures, and participant age. The primary endpoint is the change in GA lesion size at month 15.

Secondary endpoints include change in GA lesion size through month 24, visual acuity and function measures, development of macular neovascularization, and safety and tolerability. Top-line data from the study's 15-month primary endpoint are expected in late 2027, according to the company. RP